Traws Pharma Inc
$ 1.37
-7.43%
05 Jun - close price
- Market Cap 21,968,500 USD
- Current Price $ 1.37
- High / Low $ 1.46 / 1.33
- Stock P/E N/A
- Book Value -0.07
- EPS -1.87
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.90 %
- ROE -56.39 %
- 52 Week High 3.27
- 52 Week Low 1.00
About
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. The company is headquartered in Newtown, Pennsylvania.
Analyst Target Price
$5.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-15 | 2025-12-31 | 2025-11-13 | 2025-08-14 | 2025-05-15 | 2025-03-31 | 2024-11-14 | 2024-08-15 | 2024-04-01 | 2024-03-14 | 2023-11-14 | 2023-08-10 |
| Reported EPS | -0.52 | -0.5544 | -0.34 | -0.16 | 22.4413 | 26.6 | -8.81 | -4.8652 | -0.19 | -0.19 | -0.23 | -0.2 |
| Estimated EPS | -0.56 | -0.54 | -9.16 | -8.75 | -0.265 | -0.25 | -6.25 | -6.25 | -0.23 | -0.25 | -0.29 | -0.31 |
| Surprise | 0.04 | -0.0144 | 8.82 | 8.59 | 22.7063 | 26.85 | -2.56 | 1.3848 | 0.04 | 0.06 | 0.06 | 0.11 |
| Surprise Percentage | 7.1429% | -2.6667% | 96.2882% | 98.1714% | 8568.4151% | 10740% | -40.96% | 22.1568% | 17.3913% | 24% | 20.6897% | 35.4839% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TRAW
2026-06-02 19:39:19
This Simply Wall St analysis provides an overview of Traws Pharma (TRAW), a clinical-stage biopharmaceutical company. The report highlights that TRAW is significantly undervalued, trading at a substantial discount to its fair value, with revenue forecast to grow by 56.33% annually. However, it also points out several risks including past shareholder dilution, high stock volatility, negative shareholder equity, and negligible revenue.
2026-05-30 10:39:54
This page provides executive compensation details for Traws Pharma, Inc. (TRAW), although specific compensation figures are not visible. It also offers a company overview, financial data sections (income, balance sheet, cash flow), and other analytical tools like insider trading, institutional holdings, analyst ratings, and patent information. The article highlights Traws Pharma's focus on developing novel antiviral therapies.
2026-05-29 13:10:41
Traws Pharma (NASDAQ: TRAW) has issued its 2026 definitive proxy statement (DEF 14A) detailing proposals for its virtual annual meeting on July 8, 2026. The company is seeking stockholder approval to elect seven directors, amend its 2021 Incentive Compensation Plan to increase available shares by 2,000,000, ratify KPMG LLP as its independent auditor, and approve the issuance of common shares upon the exercise of Series B and Series C warrants in accordance with Nasdaq Listing Rule 5635(d). Additionally, stockholders will vote on a proposal to allow adjournment of the meeting to solicit additional proxies if needed.
2026-05-28 12:09:35
Traws Pharma Inc., a clinical-stage biopharmaceutical company based in Newtown, PA, is developing a proprietary broad-spectrum antiviral combination therapy to combat deadly viruses like Hantavirus, Ebola, and Lassa fever. The therapy uses a "dual-strike" mechanism to disrupt viral replication and minimize toxicity. The company plans to scale up chemical development and manufacturing, including expanding efforts in Nigeria, to ensure rapid response and global accessibility.
2026-05-27 16:08:46
Traws Pharma (NASDAQ: TRAW) is advancing a novel dual-strike antiviral combination to combat Hantavirus, Ebola, and potential Lassa outbreaks. The drug works by depleting host cellular nucleotides and forcing viral use of nucleoside mimics, aiming for high potency at lower doses. The program is currently in non-clinical development with plans for studies in BSL-3/BSL-4 labs and collaborations with health agencies like the CDC and NAFDAC for rapid manufacturing and global access.
2026-05-27 12:45:00
Traws Pharma has announced a new antiviral program targeting Hantavirus and Ebola outbreaks with a novel broad-spectrum combination agent. This therapy uses a dual-strike mechanism to deplete host nucleotides and force viruses to incorporate nucleoside-mimics, maximizing efficacy at lower doses. The company is fast-tracking clinical development and manufacturing, collaborating with the CDC, NAFDAC, and AMA to ensure rapid access and potential stockpiling.
